SOHO 2021 | The potential of CAR-T therapy in MCL
Michael L. Wang, MD, MD Anderson Cancer Center, Houston, TX, discusses the emerging role of chimeric antigen receptor T-cell (CAR-T) therapy in the treatment of mantle cell lymphoma (MCL). In contrast to large-cell lymphoma, the use of CAR-T therapy in MCL is still in its early stages. The first CAR-T therapy for MCL, brexucabtagene autoleucel (KTE-X19), was recently approved for relapsed MCL. Dr Wang expresses the need for more research into the use of CAR-T cell therapy in MCL, and predicts that this field will advance quickly in the near future. As more CAR-T therapies for MCL are developed, new treatment paradigms involving the combination of CAR-T and other targeted therapies may emerge. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Michael Wang, MD, PhD, has participated in consultancy work with AstraZeneca, Bayer Healthcare, BeiGene, CSTone, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno, Kite Pharma, Loxo Oncology, Miltenyi Biomedicine GmbH, Oncternal, Pharmacyclics and VelosBio; has received research funding from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Innocare, Janssen, Juno, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics and VelosBio; has received honoraria from Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, CAHON, Chinese Medical Association, Clinical Care Options, Dava Oncology, Epizyme, Hebei Cancer Prevention Federation, Imbruvica, Imedex, Janssen, Kite Pharma, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharmaceuticals, OMI, Physicians Education Resources (PER), Scripps, The First Afflicted Hospital of Zhejiang University and BGICS.
